Evolus Inc (EOLS)
Evolus, Inc. is a healthcare company listed on NASDAQ under the ticker EOLS. The company focuses on the cash-pay aesthetic market and markets its products in the United States, Canada, Europe, and Australia. Its portfolio includes Jeuveau, a purified botulinum toxin type A formulation used for the temporary improvement of moderate to severe glabellar lines in adults, and Evolysse, a range of injectable hyaluronic acid gels designed for areas such as the mid face, nasolabial folds, lips, and eyes. Evolus was incorporated in 2012 and is headquartered in Newport Beach, California.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-EOLS
|
$8.96
|
8.6% Upside
|
Fair
|
$15
|
81.8% Upside
|
Bargain
|
Good
|
0.0%
|
November 10, 2026
|
1.7x
|
544.9 M
|
664.6 M
|
23.8%
|
72.1%
|
-2.3
|
53.2%
|
